- Home
- OKYO vs CSBR Comparison
OKYO vs CSBR Comparison
Compare OKYO & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- CSBR
- Stock Information
- Founded
- OKYO 2007
- CSBR 1985
- Country
- OKYO United Kingdom
- CSBR United States
- Employees
- OKYO N/A
- CSBR N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OKYO Health Care
- CSBR Health Care
- Exchange
- OKYO Nasdaq
- CSBR Nasdaq
- Market Cap
- OKYO 97.8M
- CSBR 90.0M
- IPO Year
- OKYO 2022
- CSBR 1986
- Fundamental
- Price
- OKYO $2.22
- CSBR $6.76
- Analyst Decision
- OKYO Strong Buy
- CSBR Strong Buy
- Analyst Count
- OKYO 1
- CSBR 1
- Target Price
- OKYO $7.00
- CSBR $12.00
- AVG Volume (30 Days)
- OKYO 136.7K
- CSBR 12.2K
- Earning Date
- OKYO 07-18-2025
- CSBR 12-10-2025
- Dividend Yield
- OKYO N/A
- CSBR N/A
- EPS Growth
- OKYO N/A
- CSBR N/A
- EPS
- OKYO N/A
- CSBR 0.21
- Revenue
- OKYO N/A
- CSBR $56,878,000.00
- Revenue This Year
- OKYO N/A
- CSBR $7.31
- Revenue Next Year
- OKYO N/A
- CSBR $12.01
- P/E Ratio
- OKYO N/A
- CSBR $31.87
- Revenue Growth
- OKYO N/A
- CSBR 10.11
- 52 Week Low
- OKYO $0.90
- CSBR $4.07
- 52 Week High
- OKYO $3.35
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- OKYO 42.84
- CSBR 50.14
- Support Level
- OKYO $2.33
- CSBR $6.67
- Resistance Level
- OKYO $2.93
- CSBR $7.03
- Average True Range (ATR)
- OKYO 0.22
- CSBR 0.17
- MACD
- OKYO -0.05
- CSBR -0.00
- Stochastic Oscillator
- OKYO 10.46
- CSBR 28.95
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.